



Young patients' engagement in the European Joint Programme on Rare Diseases – EJPRD

Mariangela Lupo

European Network of Excellence for Paediatric Clinical Research

Via Luigi Porta 14, 27100 PAVIA - ITALY • VAT 01825900184

www.teddynetwork.net • info@teddynetwork.net

Can children be involved in this process?

The UN Convention on the Rights of the Child, Article 12 states Children and Young People have a right to have their views heard in all matters affecting them and for these to be taken seriously




International Convention of the Rights of the Child (UN)

**Fundamental principles underpinning
the rights of the child in Europe**

**Principles of the
“*Best interests*”
“*Evolving capacities*”
of the child**

Challenges in the engagement of children


Some key factors influence children comprehension of the information and the consequent involvement in clinical research process



Young patients engagement

❖ Engaging children early on in the research process and educating them about the importance of participating in clinical research, could help in reducing the patients' retention and fostering treatments compliance.

❖ A patient-centred approach promotes the collaboration between the different actors of the research process and should be included in the best practices of the paediatric research in order to enhance quality and relevance of the research itself.



Specifically tailored methods should be applied to the training and empowerment process of paediatric patients

- ❖ Due to the paediatric specific developmental characteristics, specifically tailored methods should be applied to the training and empowerment process of paediatric patients.
- ❖ Educate and empower the paediatric patients in the specific topic of the project for which their help is requested. For example, improve the language, content and format of the assent document.
- ❖ Dynamic interactivity to collect feedback aiming to improve the project by using the best methods to collect the information. For example, focus groups, questionnaires or surveys, personal interviews, etc.

European Joint Programme on Rare Diseases

EJP-RD aims to create a research and innovation pipeline “from bench to bedside” ensuring rapid translation of research results into clinical applications and uptake in healthcare for the benefit of patients.



European Joint Programme on Rare Diseases

- **Union contribution:** 55 M€ (70% reimbursement rate)
- **Total budget (min. submitted):** 101 M€ (→ expected > 110 M€)
- **Number of partners:** 88
- **Number of participating countries (beneficiaries and LTPs):** 35 including 27 EU MS (AT, BE, BG, CZ, DE, ES, EE, FI, FR, GR, HU, HR, IE, IT, NL, LT, LV, LU, MT, PL, PT, RO, SE, SK, SL, SV, UK), 7 associated (AM, CH, GE, IL, NO, RS TK) and third countries (CA)
- **Timeline:** Jan 2019 – Dec 2023

- **Types of partners:**
 - 33 research funding bodies/ministries
 - 12 research institutes
 - 22 universities/hospital universities
 - 11 hospitals
 - 5 EU infrastructures (BBMRI, EATRIS, ECRIN, ELIXIR, INFRAFRONTIER) + EORTC
 - EURORDIS & ePAGs
 - 6 charities/foundations (FTELE, AFM, FFRD, FGB, BSF, IT)

European Joint Programme on Rare Diseases



The specific objective of EJP-RD is to improve integration, efficacy, production and social impact of research on rare diseases through the development, demonstration and promotion of sharing of research and clinical data, materials, processes, knowledge and know-how, and an efficient model of financial support for research on rare diseases

The whole programme is based on the mixture/integration of already existing activities/programs/tools/trainings and the creation of new ones (new added value)

EJP RD STRUCTURE

**COORDINATION
& TRANSVERSAL ACTIVITIES**

INTEGRATIVE RESEARCH STRATEGY

SUSTAINABILITY

ETHICAL & REGULATORY

COMMUNICATION

1

FUNDING

2

**COORDINATED
ACCESS TO
DATA &
SERVICES**

3

**CAPACITY
BUILDING &
EMPOWERMENT**

4

**ACCELERATING
TRANSLATION
OF RESEARCH &
THERAPY
DEVELOPMENT**



WP1 COORDINATION & MANAGEMENT

WP2
STRATEGY

WP3
SUSTAINABILITY

WP4
ETHICS, LEGAL, REGULATORY & IPR

WP5
COMMUNICATION & DISSEMINATION



WP6
Joint Transnational Calls

WP7
Networking scheme

WP8
RDR Challenges

WP9
Monitoring of funded projects



WP 10
User-driven strategic planning for P2

WP 11
Virtual Platform for data & resources

WP 12
Enabling sustainable FAIRness

WP 13
Holistic approaches for rare disease diagnostics and therapeutics



WP 14
Training on data management & quality

WP 15
Capacity building and training of patients and researchers

WP 16
Online Academic education course

WP 17
ERN RD training and support programme

WP 18
Development and adaptation of training activities



WP 19
Facilitating partnerships and accelerating translation

WP 20
Validation, use and development of innovative methodologies for clinical studies

Pillar 1: funding collaborative research on RD

The Pillar will foster joint transnational calls for collaborative research projects **resulting in financial support** to third parties encompassing various aspects of rare diseases.

In addition, the financial support actions will be extended to the Networking Scheme (to encourage sharing of knowledge on rare diseases between clinicians, (biomedical) scientists and patient organizations) and the Rare Disease Research Challenges (innovative funding scheme to foster private-public partnerships and multistakeholder collaborations).



Pillar 2: Innovative coordinated access to data and services for transformative RD research

The Pillar will **develop a FAIR virtual platform for RD information** encompassing research data, samples, tools and standards to support and accelerate rare diseases research. In addition, **pilot and proof-of-concept projects will be put in place** to enable multidisciplinary, holistic approaches for rare disease diagnostics and therapeutics and fostering creation of complete diseases pathways.



Pillar 3: capacity building and empowerment

The pillar will be raising the level of knowledge and know-how within the RD research and care community, including through ERNs and RD patient representatives and advocates. The pillar foresees the development of:

- ❖ a **comprehensive programme of training courses** will tackle areas such as research data management, orphan drug development, HTA & regulatory processes, best practice guidelines and ERN cross-cutting themes & needs.
- ❖ training courses will be developed and adapted to address the specific needs of EU13 countries
- ❖ first-in-Europe online academic course to provide an EU-wide **streamlined education programme on RD** research to all interested stakeholders.



Pillar 4: accelerating the translation of high potential projects and improving outcomes of clinical studies in small populations

By creating a bridge between basic research and medical innovation, otherwise known as the “bench to bedside” approach, this pillar aims to support the RD community to more effectively translate high quality research into high impact interventions for the RD patient community. To this aim:

- ❖ Research projects funded through Pillar 1 and previously by E-Rare will be selected for their translational potential and specifically supported and guided throughout this process.
- ❖ Pillar 4 will foster the development of innovative methodologies tailored for clinical studies in RDs by specifically supporting ERNs to use the most adapted methodologies improving trial studies in RDs.
- ❖ Demonstration studies will be funded to validate existing and most recently presented innovative methodologies as well as most promising new statistical methodologies;

TEDDY INVOLVEMENT

**COORDINATION
& TRANSVERSAL ACTIVITIES**

INTEGRATIVE RESEARCH STRATEGY

SUSTAINABILITY

ETHICAL & REGULATORY

COMMUNICATION

1

FUNDING

2


**COORDINATED
ACCESS TO
DATA &
SERVICES**

3

**CAPACITY
BUILDING &
EMPOWERMENT**

4

**ACCELERATING
TRANSLATION
OF RESEARCH &
THERAPY
DEVELOPMENT**





PILLAR 3

W

T
d
s
E

The overall objective of this WP is to address one key component of the EJP on RD that is to improve RD research and innovation and to enhance the uptake of research results by building the capacity of the patient community and other key stakeholders.

WP15: Capacity building & training of patients and researchers in rare diseases research and processes

Expert Patients and Researchers EURORDIS Summer school – scientific innovation and translation research aspects in RDS for patient advocates – leadership & communication skills for patient advocates and representatives – education material and activities for paediatric patients

WP16: Online academic education course

Based on assessed needs of the RD community – in collaboration with universities – 10 to 12 modules with accreditation – e-learning format open to all – Future Learn platform

WP17: ERN RD training & support programmes

NETWORK

TEDDY LEADS TASK 15.4

Educational materials and activities for paediatric patients

The planned activities include short workshops in collaboration with Fundació Sant Joan de Deu, EURORDIS and the eYPAGnet (the European Young Persons' Advisory Group network) for 15 patients' representatives focusing on the following areas:

- ❖ Genetic /rare disease characteristics and evolution
- ❖ Role for paediatric patients and relevance of clinical and translational research (including patients' engagement in clinical trials, the consent issue, the patient-reported outcomes in the context of paediatric rare diseases)
- ❖ Orphan Medicinal Products availability and access for paediatric patients on the EU market, pharmacovigilance and off-label use in paediatric setting

TEDDY LEADS TASK 15.4

Educational materials and activities for paediatric patients

The Face to Face 'paediatric patient experts training course' will be hosted in Italy (TEDDY), Spain (JSJD) and France (EURORDIS).



TEDDY as contributing entity

- TEDDY is among the few organisations whose members have been considered in the Consortium Agreement as Contributing Entities and have rights to access to the Background and the Results of the project at the conditions set out in the Consortium Agreement.
- This is a very important achievement as it means that TEDDY members are considered in the project as EJPRD Linked Third parties, in the same way as the members of the involved ERICs and ERNs.

**COORDINATION
& TRANSVERSAL ACTIVITIES**

INTEGRATIVE RESEARCH STRATEGY

SUSTAINABILITY

ETHICAL & REGULATORY

COMMUNICATION

1

FUNDING

2

**COORDINATED
ACCESS TO
DATA &
SERVICES**

3

**CAPACITY
BUILDING &
EMPOWERMENT**

4

**ACCELERATING
TRANSLATION
OF RESEARCH &
THERAPY
DEVELOPMENT**

COORDINATION & TRANSVERSAL ACTIVITIES

PROGRAMME MANAGEMENT & COORDINATION


INTEGRATIVE RESEARCH & INNOVATION STRATEGY

SUSTAINABILITY

ETHICS, LEGAL, REGULATORY & IPR

COMMUNICATION & DISSEMINATION

TEDDY will be involved in the project in the communication activities. It will provide its experience in the field of paediatrics, ensuring the right awareness on the importance of the paediatric aspects in the field of the rare disease research.



CONCLUSIONS

TEDDY will be central to further engage and empower rare disease patients into research and provide them with the tools required to apprehend and actively contribute to innovation and therapy development.

There will also be relevant links and synergies with the ongoing H2020 project EPTRI European Paediatric Translational Research Infrastructure, coordinated by CVBF, the H2020 project PEDCRIN Paediatric Clinical Research Infrastructure Network coordinated by ECRIN and with the IMI2 C4C project.